Molecular Partners, Novartis Say Covid-19 Drug Ensovibep Mee

BASEL (dpa-AFX) - Molecular Partners AG (MOLN) and Novartis announced positive data from phase 2 study for Ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19.A total of 407 patients

Related Keywords

, Novartis , Antiviral Therapeutic , Molecular Partners , Molecular , Partners , Covid , Drug , Ensovibep , Meets , Goals , Hase , Study ,